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Abstract
Background: Thyroid incidentaloma is defined as an unsuspected thyroid lesion found on imaging study or while
performing a surgery non-related to the thyroid gland. Most recent scientific literature tends to demonstrate a
detection rate of 0.1–4.3% for incidental findings of thyroid focal uptake identified by 18F-fluorodeoxyglugose
Positron Emission Tomography with computed tomography (18FDG-PET/CT) initially prescribed for nonthyroid
disease. From 10.3 to 80.0% of patients who underwent further evaluation are diagnosed with malignant lesions.
Our first objective is to determine the risk of malignancy confined in thyroid incidentalomas(IT) detected on 18FDG-
PET/CT in patients treated in a tertiary care center (Centre Hospitalier Universitaire de Sherbrooke). Second, we want
to identify a cut-off value for SUVmax in order to distinguish benign from malignant IT. Third, we look for predictive
criterion that can be outlined to help in their management.
Methods: We retrospectively reviewed 40 914 charts of patients who had a 18FDG-PET/CT done in a tertiary center
from 2004 to 2014. For each patient where a thyroid incidentaloma has been identified, Maximum Standardized
Uptake Value (SUVmax), ultrasound report, cytology and histopathological results as well as oncologic outcomes
were compiled and analyzed.
Results: In this study, the incidence for thyroid incidentaloma detected with 18FDG-PET/CT is 0.74%. The rate of
malignancy present in IT is 8.2% based on histopathological results. Of the patients who underwent surgery, thyroid
malignancy was identified in 54.3% of them. Cytoponction showed a strong correlation with final histopathological
results (p = 0.009).
Conclusion: Thyroid incidentalomas detected with 18FDG-PET/CT are relatively infrequent, but the potential risk of
malignancy remains elevated. Fine needle aspiration biopsy is the investigation of choice to rule out a malignant
incidentaloma when there is no other element in the clinical portrait to preclude such additional work up.
Keywords: Thyroid incidentalomas, 18F-fluorodeoxyglugose Positron Emission Tomography with computed
tomography, Malignancy risk, Algorithm, SUV
Background
Thyroid incidentaloma (TI) is defined as a thyroid gland
lesion fortuitously discovered during radiology exams, like
computed tomography or ultrasound. This type of lesion
can also be identified during a neck surgery unrelated to
the thyroid. 18F-fluorodeoxyglugose Positron Emission
Tomography with computed tomography (18FDG-PET/
CT) is a nuclear medicine imaging technique based on
glucose hypermetabolism from malignant cells. It is
indicated mostly for detection and follow up in patients
with malignancies. In this regard, 18FDG-PET/CT for
detection of malignancies amongst thyroid focal uptake
has a sensitivity of 100%, a specificity of 69%, a positive
predictive value (PPV) of 62% and a negative predictive
value (NPV) of 100% [1]. Other studies report values ran-
ging from 60 to 80% for sensitivity and from 66.1 to 91.0%
for specificity [2]. Iagaru et al., regarding a different pa-
tient population with confirmed thyroid carcinoma, stated
that 18FDG-PET/CT has a high sensitivity (88.6%) and
specificity (89.3%) when used for follow up [3].
The popularity of the 18FDG-PET/CT leads to an in-
creasing number of thyroid incidentalomas, or any other
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type of unexpected site of hypermetabolism interpreted
as suspicious for malignancy. As thyroid glucose uptake
can be nonspecific, the prevalence of malignancies
amongst thyroid incidentalomas is still uncertain. While
a recent meta-analysis identified a rate of malignancy of
19.8% [4], in other studies, the prevalence of TI detected
by 18FDG-PET/CT ranged from 0.1 to 4.3% and the risk
of malignancy stands between 10.3 and 80.0% [5–12].
In this retrospective study, we benefit from Sher-
brooke’s significant experience with 18FDG-PET/CT to
review the data related to thyroid incidentalomas and to
estimate the risk of malignancy for such lesions. The
secondary objective was to determine a threshold value
for the Maximum Standardized Uptake Value (SUVmax)
where a TI could be considered as malignant. We also




Between August 1st 2004 and August 1st 2014, a total of
40 914 18FDG-PET/CT were done in the Centre Hospi-
talier Universitaire de Sherbrooke (CHUS). Of those,
1369 patients were extracted after we questioned CIR-
ESS data bank with the keywords in french «thyroid»,
«thyroid nodule» and «thyroid incidentalomas» to be
written in the nuclear medicine final report. We indi-
vidually reviewed the 1369 charts and, from those, 304
patients with thyroid incidentalomas were identified.
The remaining 1065 files were excluded on the basis of
the following exclusions criteria:
(i) Known thyroid nodule or thyroid disease
documented in the final report or in the patient’s
chart
(ii)18FDG-PET/CT specifically done for thyroid disease
(iii)Absence of documentation available in our
institution in pre- or post-18FDG-PET/CT patient’s
chart.
For each patient with a thyroid incidentaloma, the
presence of complementary investigations, including
neck ultrasound and fine-needle aspiration cytology re-
sults were noted. For neck ultrasound, we stratified the
results as low risk, suspect or malignant. In the ATA
guidelines 2015, ultrasonographic criteria suspicious for
malignancy are: presence of microcalcifications, nodule
hypoechogenicity compared with the surrounding thy-
roid or strap muscles, irregular margins (defined as ei-
ther infiltrative, microlobulated or spiculated) and a
shape taller than wide measured on a transverse view
[13]. Based on final report from radiologist, ultrasound
was low risk when no criteria or only hypoechogenicity
was encountered. A suspect ultrasound had two or three
criteria mentioned and malignant ultrasound had four
suspicious features.
FNA results were reported according to Bethesda
system for reporting of thyroid cytopathology: Bethesda
1 (Non-diagnostic/Unsatisfactory) lied in the non-
diagnostic category. Bethesda 2 and 3 (Benign or AUS/
FLUS) were put in the low risk category. Bethesda 4
(Follicular neoplasm) was stratified as intermediary and
Bethesda 5 and 6 (Suspicious for malignancy and Malig-
nant) were put in the high risk category [14]. Finally,
when available, the histopathological results were also
compiled as benign or malignant.
18FDG-PET/CT
All the 18FDG-PET/CT exams were done according to
the standard nuclear medicine department protocol in
our institution. If the size(cm) of the TI or its SUVmax
was missing, the exam was re-read by the nuclear medi-
cine specialist attached to this study.
Statistical analysis
The Mann–Whitney U Test or a logistic regression ana-
lysis were used with continuous variables to determine if
they were predictive values for malignancy in thyroid
incidentalomas. The exact test of Fisher or a Chi2 (χ2)
were used for dichotomous or categorical variables. Data
were analyzed by IBM SPSS Statistics 20. A p value less
than 0.05 determined the threshold of a statistically sig-
nificant difference. Air under the curve (AUC) was used
from a ROC curve to identify a SUVmax cut-off value.
Results
Of the 40 914 18FDG-PET/CT done in Sherbrooke
between 2004 and 2014, 304 (0.74%) thyroid incidentalo-
mas were identified. Amongst these 304 TI, further
evaluation, including a medical follow-up, an ultrasound
and/or a fine-needle aspiration (FNA), was performed in
215 of them (Fig. 1). Hundred and fifty-nine patients
underwent an FNA and the results based on the Be-
thesda system are illustrated in the Fig. 2. One patient
from the “ultrasound only” group and one in the “clin-
ical follow up” group went for surgery, 5 from the “FNA
only” group and 39 from the “ultrasound and FNA”
group. Histopathologic confirmation from surgery was
obtained in 46 patients. Of those, 21 were low risk based
on the FNA, 5 were intermediate and 18 were high risk.
Two surgical patients did not have any FNA done pre-
operatively. Twenty-five patients out of 46 (54.3%) were
confirmed with a malignant thyroid lesion: 18 papillary
carcinomas, 4 follicular carcinomas, 1 anaplastic carcin-
oma of the thyroid, 1 metastasis of a neuroendocrine
tumor and 1 non-hodgkinian lymphoma B-cell subtype.
Clinical characteristics of patients with a comparison
of 18FDG-PET/CT findings and histopathological results
Hagenimana et al. Journal of Otolaryngology - Head and Neck Surgery  (2017) 46:22 Page 2 of 7
of operated patients are shown in Table 1. After statis-
tical analysis, sex (male) and fine-needle aspiration
results were the potent predictors of thyroid malignancy
(p value = 0.008 and 0.002, respectively). Neither SUV-
max nor thyroid incidentaloma size measured in cm on
TEP/CT were predictors of malignancy (p value = 0.499
and 0.873, respectively). Neck ultrasound failed to be
within statistical significance.
Figure 3 represents the distribution of SUVmax
whether the lesion was benign or malignant on final
histopathological report. Highest SUVmax in malignant
nodule was 55.0 while it reached 9.4 for benign inciden-
talomas. Every thyroid incidentalomas (n = 3) with a
SUVmax value ≥10.8 were malignant but no SUVmax
cut-off was clearly identifiable to distinguish malignant
from benign lesion on the 18FDG-PET/CT.
Fig. 1 Flow diagram for patients with Thyroid Incidentalomas (TI) at the CHUS, between 2004 and 2014
Fig. 2 Cytology results in patients who underwent FNA
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Once the 18FDG-PET/CT was done, further investiga-
tions in our hospital (CHUS) were not performed in 89
of the 304 patients (29.4%) with thyroid incidentalomas.
Reasons varied from refusal of additional workup, lost at
clinical follow-up to extensive disease with a critical vital
prognosis. In fact, more patients were deceased in the
«No additionnal work up» group [51/84 (60.7%)] com-
pared to the group «With additional work up» [62/200
(31.0%)] (p < 0.001). We also noted that patients without
additional investigations had thyroid incidentaloma’s
SUVmax and size values inferior to those who undergo
additional workup (p < 0.001 and p = 0.002 respectively)
(Table 2).
Discussion
Thyroid incidentalomas and PET/CT inspired a large
amount of clinical research recently as this nuclear
medicine tool for imaging increased in popularity for
cancer diagnosis and follow up. Previous studies
reported a detection rate for thyroid incidentalomas
identified with 18FDG-PET/CT of 0.1 to 4.3% [5–12, 15],
and a risk of malignancy between 10.3 to 80.0% [5–12]
(Table 3). At our institution, the prevalence of incidenta-
lomas was 0.74%, which is similar to the data of studies
that included a large number of patients, like ours [5, 6,
11, 16]. A recent systematic review and meta-analysis
published in 2014 by Nayan et al. stated that the pooled
proportion of malignancy was calculated as 19.8%.
Thirty-one studies were included in this review for a
total of 197,296 PET studies and 3659 focal thyroid inci-
dentalomas [4]. In our cohort, more than half of the op-
erated patients (25/46) were diagnosed with malignancy.
This represents a rate for malignancy of 54.3% in pa-
tients who underwent a lobectomy or a thyroidectomy.
This high rate should not be interpreted as a rate of ma-
lignancy for TI knowing that a majority of patients with
TI (n = 258) do not have a final histopathological result.
Some studies [5–12, 15] have reported malignancy risk
based on the surgical patients alone, which is a misinter-
pretation since these specific studies had a minority of
patients brought to surgery for definitive diagnosis. From
our data, we can then propose that the minimal rate of
malignancy for thyroid incidentalomas is 8.2% (25/304)
in this specific cohort. Even if we extrapolate and
Table 1 Clinical characteristics of surgical patients with thyroid
incidentalomas (n = 46)
Characteristics Malignant Benign p
(n = 25) (n = 21)
Age (years) 61.88 ± 12.07 61.86 ± 10.27 0.996
Sex (M/F) 14/11 4/18 0.008
SUVmax 4.90 [2.95–8.65] 4.40 [3.55–7.73] 0.499
Sizea (cm) 1.50 [1.10–2.25] 1.45 [1.13–1.68] 0.873
Ultrasoundb 0.264
Low risk n (%) 5 (38.5) 8 (61.5)
Suspect n (%) 13 (54.2) 11 (45.8)
Malignant n (%) 3 (100.0) 0 (0.0)
Cytoponctionc 0.009
Low risk n (%) 3 (30.0) 7 (70.0)
Intermediate n (%) 6 (46.2) 7 (53.8)
High risk n (%) 14 (82.4) 3 (17.6)
Non diagnostic n (%) 2 (33.3) 4 (66.6)
aFrom the PET/CT
bBased on radiology report of suspicious features for malignancy according to
ATA guidelines 2015 (Low risk = no suspicion or hypoechogenic nodule with
no other features, suspect = 2 or 3 suspicious features, malignant = 4
suspicious features)
cAccording to the Bethesda system for reporting thyroid cytopathology
Data are shown as Mean ± standard deviation, Median [IQR] unless
otherwise indicated
Fig. 3 SUV values of thyroid incidentalomas identified with 18FDG-PET/CT compared to the histopathologic results (n = 46)
Hagenimana et al. Journal of Otolaryngology - Head and Neck Surgery  (2017) 46:22 Page 4 of 7
include the non-surgical patients with FNA results of
Bethesda 6 (malignant), this rate rises to 9.2%, which is
clinically unsignificant. In contrast, if we use the 61 non-
surgical patients with FNA results of Bethesda 2 (be-
nign) and the 21 surgical patients with a “Benign” final
histopathological result, we can again extrapolate that
26.9% of the TI were benign. Thus, the rate of malig-
nancy has to lie between 8.2 and 73.1%. Nevertheless,
this value (8.2%) is certainly compatible with an under-
estimation of the real malignancy rate in TI and the
exact value stays unrevealed in this cohort.
Our second objective was to determine a cut-off value
for the SUVmax. In general, malignant lesions have
higher glucose metabolism than benign lesions, hence a
higher SUVmax value. Similarly to Yang et al., we were
not able to determine a specific SUVmax cut-off value
that could offer a distinction between benign and malig-
nant lesions [5]. In fact, in our study, malignant lesions
had higher mean SUVmax values than benign lesions,
but the difference was not statistically significant (p =
0.499). In addition, one patient was probably operated
on the sole basis of a high SUVmax value (SUVmax =
55), since the cytology and echography results were
intermediate and low risk respectively. Histopathological
report confirmed the presence of a Hurtle cell follicular
carcinoma. This is consistent with the proposition where
lesions with frankly elevated SUV values present an
increased risk of malignancy, but a cut-off value has yet
to be determined. A recent Meta-analysis reported a
cut-off value for the SUVmax of 3.3 [17]. Indeed, the au-
thors state that this value has a good sensitivity (82.4%)
but could bring a high proportion of false negative (spe-
cificity = 36.8%), probably related with an undeniable
overlap in the SUVmax between benign and malignant
thyroid incidentalomas. In the same study, half of the
study pooled did not have a difference statistically sig-
nificant of the mean SUVmax for malignant vs benign
lesions. This confirms how inconsistent are the values in
the published series and warrant further studies.
Literature shows a great amount of variability in the
management of patients with thyroid incidentalomas,
making it a dilemma for clinicians. More recently, guide-
lines from the American Thyroid Association recom-
mended that all sonographically confirmed thyroid
nodule >1 cm incidentally discovered on 18FDG-PET/
CT should be biopsied with an FNA [13]. Moreover, this
study tried to shed some light on TI management,
especially for patients medically fit for surgery, but some
degree of uncertainty still persists since nearly a third
(29.4%) of our patients did not get any further evalu-
ation. Table 3 shows that the insecurity of their progno-
sis influenced the decision in regards of TI investigation
while more patients were deceased in this group than in
the group with further investigations.
Despite the lack of a prospective cohort, we tried to
propose a practical management algorithm for thyroid
incidentalomas discovered with 18FDG-PET/CT. Ac-
cording to our data, it was difficult to simplify the ATA
recommendation on this specific clinical problem. The
cytoponction, in our study, had a strong correlation with
final histopathological result in surgical patients. It
certainly has to remain the key element in the manage-
ment of those lesions. Emphasis should be put on a
comprehensive thyroid physical examination and an
evaluation of the vital prognosis of the patient related to
the underlying disease. This will help the clinician to
Table 2 Follow-up of patients with thyroid incidentalomas








Deceased/Alivea 51/33 62/138 <0.001
SUVmax 1.5 [0.0–3.0] 3.3 [2.1–4.6] <0.001
Size (cm) 1.0 [0.8–1.4] 1.3 [1.0–1.7] 0.002
aData on deceased/alive status were available for 84/89 patients without
follow-up and 200/215 patients with follow-up
Data are shown as Mean ± standard deviation, Median [IQR] unless
otherwise indicated
Table 3 Characteristics of previous studies on thyroid incidentalomas identified with 18FDG-PET/CT or PET alone






Jamsek et al. [15] 2015 Retrospective PET/CT 5911 230 (3.89) 18 15.2 (10/66)
Pagano et al. [6] 2011 Retrospective PET/CT 10 881 191 (1.8) 52 28.9 (15/52)
Yang et al. [5] 2012 Retrospective PET/CT 15 948 395 (2.5) 43 29.5 (43/146)
Kao et al. [10] 2012 Retrospective PET/CT 942 21 (2.2) 6 50 (3/6)
Nilsson et al. [8] 2011 Retrospective PET/CT 3641 64 (1.8) 27 25 (16/64)
Ohba et al. [9] 2010 Prospective PET 1501 20 (1.3) 20 55 (11/20)
Kim et al. [16] 2010 Retrospective PET/CT 11 623 159 (1.4) 159 23.3 (37/159)
King et al. [11] 2007 Retrospective PET et PET/CT 15 711 22 (0.1) 22 13.6 (2/22)
Yi et al. [12] 2005 Retrospective PET/CT 140 6 (4.3) 5 80.0 (4/5)
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decide if it is still pertinent to refer the patient for fur-
ther investigations, at least a cytoponction and a neck
ultrasound.
Limitations of the study
Some limitations are worth mentioning. First, the retro-
spective nature of our study. Second, the selection bias
that underestimates the prevalence of thyroid incidenta-
lomas. In fact, many patients had a fortuitous lesion iden-
tified on the 18FDG-PET/CT that was not possible to
confirm with their chart because we selected the popula-
tion of patient treated in our center in Sherbrooke. A
centralised electronic record available throughout the
province would have overstep this bias. Third, like many
other studies done previously, we do not have histopatho-
logic confirmation for the vast majority of TI for reasons
mentioned above.
Conclusion
Thyroid incidentalomas detected with 18FDG-PET/CT
are relatively infrequent, but the potential risk of malig-
nancy remains elevated. Fine needle aspiration biopsy is
the investigation of choice to rule out a malignant inci-
dentaloma when there is no other element in the clinical
portrait to preclude such additional work up. Clinicians
should keep a high index of suspicion for TI, while more
than half of patients who underwent surgery received a
malignant diagnosis. More prospective studies are
needed to confirm a valid SUVmax cut-off value and to
add some useful information for TI management.
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